These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

228 related articles for article (PubMed ID: 26951837)

  • 1. Progress on Covalent Inhibition of KRAS(G12C).
    Westover KD; Jänne PA; Gray NS
    Cancer Discov; 2016 Mar; 6(3):233-4. PubMed ID: 26951837
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Drugging K-Ras
    Ni D; Li X; He X; Zhang H; Zhang J; Lu S
    Pharmacol Ther; 2019 Oct; 202():1-17. PubMed ID: 31233765
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Potent and Selective Covalent Quinazoline Inhibitors of KRAS G12C.
    Zeng M; Lu J; Li L; Feru F; Quan C; Gero TW; Ficarro SB; Xiong Y; Ambrogio C; Paranal RM; Catalano M; Shao J; Wong KK; Marto JA; Fischer ES; Jänne PA; Scott DA; Westover KD; Gray NS
    Cell Chem Biol; 2017 Aug; 24(8):1005-1016.e3. PubMed ID: 28781124
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Drugging all RAS isoforms with one pocket.
    Kessler D; Bergner A; Böttcher J; Fischer G; Döbel S; Hinkel M; Müllauer B; Weiss-Puxbaum A; McConnell DB
    Future Med Chem; 2020 Nov; 12(21):1911-1923. PubMed ID: 32779487
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Drugging the Undruggable: Advances on RAS Targeting in Cancer.
    Molina-Arcas M; Samani A; Downward J
    Genes (Basel); 2021 Jun; 12(6):. PubMed ID: 34200676
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Selective Inhibition of Oncogenic KRAS Output with Small Molecules Targeting the Inactive State.
    Patricelli MP; Janes MR; Li LS; Hansen R; Peters U; Kessler LV; Chen Y; Kucharski JM; Feng J; Ely T; Chen JH; Firdaus SJ; Babbar A; Ren P; Liu Y
    Cancer Discov; 2016 Mar; 6(3):316-29. PubMed ID: 26739882
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The reactivity-driven biochemical mechanism of covalent KRAS
    Hansen R; Peters U; Babbar A; Chen Y; Feng J; Janes MR; Li LS; Ren P; Liu Y; Zarrinkar PP
    Nat Struct Mol Biol; 2018 Jun; 25(6):454-462. PubMed ID: 29760531
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Discovery and biological evaluation of 1-{2,7-diazaspiro[3.5]nonan-2-yl}prop-2-en-1-one derivatives as covalent inhibitors of KRAS G12C with favorable metabolic stability and anti-tumor activity.
    Imaizumi T; Akaiwa M; Abe T; Nigawara T; Koike T; Satake Y; Watanabe K; Kaneko O; Amano Y; Mori K; Yamanaka Y; Nagashima T; Shimazaki M; Kuramoto K
    Bioorg Med Chem; 2022 Oct; 71():116949. PubMed ID: 35926326
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Modeling receptor flexibility in the structure-based design of KRAS
    Zhu K; Li C; Wu KY; Mohr C; Li X; Lanman B
    J Comput Aided Mol Des; 2022 Aug; 36(8):591-604. PubMed ID: 35930206
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting KRAS Mutant Cancers with a Covalent G12C-Specific Inhibitor.
    Janes MR; Zhang J; Li LS; Hansen R; Peters U; Guo X; Chen Y; Babbar A; Firdaus SJ; Darjania L; Feng J; Chen JH; Li S; Li S; Long YO; Thach C; Liu Y; Zarieh A; Ely T; Kucharski JM; Kessler LV; Wu T; Yu K; Wang Y; Yao Y; Deng X; Zarrinkar PP; Brehmer D; Dhanak D; Lorenzi MV; Hu-Lowe D; Patricelli MP; Ren P; Liu Y
    Cell; 2018 Jan; 172(3):578-589.e17. PubMed ID: 29373830
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Therapeutic targeting of RAS: New hope for drugging the "undruggable".
    Khan I; Rhett JM; O'Bryan JP
    Biochim Biophys Acta Mol Cell Res; 2020 Feb; 1867(2):118570. PubMed ID: 31678118
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Drugging an undruggable pocket on KRAS.
    Kessler D; Gmachl M; Mantoulidis A; Martin LJ; Zoephel A; Mayer M; Gollner A; Covini D; Fischer S; Gerstberger T; Gmaschitz T; Goodwin C; Greb P; Häring D; Hela W; Hoffmann J; Karolyi-Oezguer J; Knesl P; Kornigg S; Koegl M; Kousek R; Lamarre L; Moser F; Munico-Martinez S; Peinsipp C; Phan J; Rinnenthal J; Sai J; Salamon C; Scherbantin Y; Schipany K; Schnitzer R; Schrenk A; Sharps B; Siszler G; Sun Q; Waterson A; Wolkerstorfer B; Zeeb M; Pearson M; Fesik SW; McConnell DB
    Proc Natl Acad Sci U S A; 2019 Aug; 116(32):15823-15829. PubMed ID: 31332011
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Getting a Handle on RAS-targeted Therapies: Cysteine Directed Inhibitors.
    Huynh MV; Campbell SL
    Mini Rev Med Chem; 2016; 16(5):383-90. PubMed ID: 26423694
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Covalent inhibitor targets KRas
    Li HY; Qi WL; Wang YX; Meng LH
    Genes Dis; 2023 Mar; 10(2):403-414. PubMed ID: 37223497
    [No Abstract]   [Full Text] [Related]  

  • 15. Quantitative Systems Pharmacology Analysis of KRAS G12C Covalent Inhibitors.
    Stites EC; Shaw AS
    CPT Pharmacometrics Syst Pharmacol; 2018 May; 7(5):342-351. PubMed ID: 29484842
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Small-Molecule Inhibitors Directly Targeting KRAS as Anticancer Therapeutics.
    Chen H; Smaill JB; Liu T; Ding K; Lu X
    J Med Chem; 2020 Dec; 63(23):14404-14424. PubMed ID: 33225706
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mutant-Specific Targeting of Ras G12C Activity by Covalently Reacting Small Molecules.
    Goody RS; Müller MP; Rauh D
    Cell Chem Biol; 2019 Oct; 26(10):1338-1348. PubMed ID: 31378709
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The dominant role of G12C over other KRAS mutation types in the negative prediction of efficacy of epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer.
    Fiala O; Pesek M; Finek J; Benesova L; Belsanova B; Minarik M
    Cancer Genet; 2013; 206(1-2):26-31. PubMed ID: 23313110
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fragment Optimization of Reversible Binding to the Switch II Pocket on KRAS Leads to a Potent, In Vivo Active KRAS
    Bröker J; Waterson AG; Smethurst C; Kessler D; Böttcher J; Mayer M; Gmaschitz G; Phan J; Little A; Abbott JR; Sun Q; Gmachl M; Rudolph D; Arnhof H; Rumpel K; Savarese F; Gerstberger T; Mischerikow N; Treu M; Herdeis L; Wunberg T; Gollner A; Weinstabl H; Mantoulidis A; Krämer O; McConnell DB; W Fesik S
    J Med Chem; 2022 Nov; 65(21):14614-14629. PubMed ID: 36300829
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeted Degradation of Oncogenic KRAS
    Bond MJ; Chu L; Nalawansha DA; Li K; Crews CM
    ACS Cent Sci; 2020 Aug; 6(8):1367-1375. PubMed ID: 32875077
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.